Lynch, K., Chapman, R., Keshav, S., Montano-Loza, A., Mason, A., Kremer, A., . . . Levy, C. (2019). Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Elsevier.
Chicago-čujuhus (17. p.)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
MLA-čujuhus (9. p.)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.